Rare immune disease drug shows real-world quality-of-life gains beyond clinical trials
A new analysis of patient experiences with leniolisib, a treatment for ultra-rare activated PI3Kδ syndrome, found that 86% of patients reported meaningful improvements in daily life—not just lab markers. The findings suggest a broader market opportunity for precision immunotherapies targeting rare genetic disorders, and demonstrate the commercial value of capturing patient-reported outcomes early in drug development.
Originaltitel: Evaluating the impact of leniolisib treatment on symptoms and health-related quality of life in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome
Purpose Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) is an ultra-rare inborn error of immunity, characterised by immune deficiency and dysregulation. In a randomised controlled trial (RCT; NCT02435173) and open-label extension (OLE; NCT02859727), leniolisib, a selective PI3Kδ inhibitor, was efficacious and well-tolerated in individuals with APDS. These trials suggested some improvements with leniolisib in health-related quality of life (HRQoL) using generic instruments, with other anecdotal evidence also describing improvements in specific domains. Here, all available qualitative data relating to treatment experience were systematically assessed to evaluate any perceived impacts of leniolisib on patients’ lives. Methods Changes in APDS-related symptoms and patient HRQoL were assessed using unsolicited qualitative data captured from 36 leniolisib-treated individuals: RCT and OLE clinician-recorded, open-text patient narratives (n=31); case reports (n=4); standalone qualitative study conducted with APDS patient/caregiver interviews/narratives (n=1). Results Improvements in APDS-related symptoms and HRQoL were reported following treatment with leniolisib: 86.1% (31/36) of individuals mentioned improvements in ≥1 symptom/HRQoL impact. Of these, 87.1% (27/31) explicitly attributed ≥1 improvement to leniolisib. One-third (12/36) of individuals explicitly attributed improvements in fatigue/energy to leniolisib. This was associated with reported HRQoL improvements explicitly attributed to leniolisib: physical activity (33.3% [12/36]), work/school performance/attendance (13.9% [5/36]) and travel ability (8.3% [3/36]). Moreover, 36.1% (13/36) of participants explicitly attributed improvements in their overall wellbeing to leniolisib. Conclusion As data were unsolicited and baseline symptoms/HRQoL were not available, results may not represent all changes experienced, and is not possible to determine the amount of change in symptoms/HRQoL associated with leniolisib. Nevertheless, these analyses indicate that participants with APDS experienced improvements in symptoms and overall wellbeing following treatment with leniolisib.